Cytarabine controlled-release - Pacira BioSciences
Alternative Names: Cytarabine liposomal; cytarabine liposome injection - Pacira BioSciences; Cytarabine sustained-release; DepoCyt; DepoCyte; DepoFoam Encapsulated Cytarabine; DTC 101; NS-101 - Pacira BioSciences; SavedarLatest Information Update: 12 Jan 2022
At a glance
- Originator SkyePharma Inc
- Developer IRCCS San Raffaele; Mundipharma International; Pacira BioSciences; Pacira Pharmaceuticals
- Class Antineoplastics; Arabinonucleosides; Pyrimidine nucleosides; Small molecules
- Mechanism of Action DNA synthesis inhibitors; DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Lymphomatous meningitis; Meningeal carcinomatosis
- No development reported Neoplastic meningitis
- Discontinued B-cell lymphoma
Most Recent Events
- 09 Apr 2021 Discontinued - Phase-II for B-cell lymphoma in Italy (Intrathecal) (Pacira BioSciences pipeline, April 2021)
- 09 Apr 2019 Pacira Pharmaceuticals is now called Pacira BioSciences
- 17 Jul 2017 No recent reports on development identified - Phase-II for B-cell lymphoma in Italy (Intrathecal)